References
Bab I and
Zimmer A
(2009)
Cannabinoid receptors and the regulation of bone mass.
British Journal of Pharmacology
153(2):
182–188.
Bisogno T and
Di Marzo V
(2007)
Short‐ and long‐term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders.
Pharmacological Research
56(5):
428–442.
Bisogno T and
Di Marzo V
(2010)
Cannabinoid receptors and endocannabinoids: role in neuroinflammatory and neurodegenerative disorders.
CNS & Neurological Disorders – Drug Targets
9(5):
564–573.
Bisogno T,
Howell F,
Williams G et al.
(2003)
Cloning of the first sn1‐DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain.
Journal of Cell Biology
163(3):
463–468.
Bisogno T,
Sepe N,
Melck D et al.
(1997)
Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2‐arachidonoylglycerol in mouse neuroblastoma cells.
Biochemical Journal
322(2):
671–677.
Blankman JL,
Simon GM and
Cravatt BF
(2007)
A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2‐arachidonoylglycerol.
Chemistry & Biology
14(12):
1347–1356.
Blázquez C,
Chiarlone A,
Sagredo O et al.
(2011)
Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
Brain
134(Pt 1):
119–136.
Catani MV,
Fezza F,
Baldassarri S et al.
(2009)
Expression of the endocannabinoid system in the bi‐potential HEL cell line: commitment to the megakaryoblastic lineage by 2‐arachidonoylglycerol.
Journal of Molecular Medicine
87(1):
65–74.
Cobellis G,
Ricci G,
Cacciola G et al.
(2010)
A gradient of 2‐arachidonoylglycerol regulates mouse epididymal sperm cell start‐up.
Biology of Reproduction
82(2):
451–458.
Cravatt BF,
Giang DK,
Mayfield SP et al.
(1996)
Molecular characterization of an enzyme that degrades neuromodulatory fatty‐acid amides.
Nature
384(6604):
83–87.
Cristino L,
Starowicz K,
De Petrocellis L et al.
(2008)
Immunohistochemical localization of anabolic and catabolic enzymes for anandamide and other putative endovanilloids in the hippocampus and cerebellar cortex of the mouse brain.
Neuroscience
151(4):
955–968.
Devane WA,
Dysarz FA 3rd,
Johnson MR et al.
(1988)
Determination and characterization of a cannabinoid receptor in rat brain.
Molecular Pharmacology
34(5):
605–613.
Devane WA,
Hanus L,
Breuer A et al.
(1992)
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
Science
258(5090):
1946–1949.
Di Marzo V
(2008)
Targeting the endocannabinoid system: to enhance or reduce?
Nature Reviews Drug Discovery
7(5):
438–455.
Di Marzo V
(2010)
Anandamide serves two masters in the brain.
Nature Neuroscience
13(12):
1446–1448.
Di Marzo V
(2011)
Endocannabinoid signaling in the brain: biosynthetic mechanisms in the limelight.
Nature Neuroscience
14(1):
9–15.
Di Marzo V and
Després JP
(2009)
CB1 antagonists for obesity – what lessons have we learned from rimonabant.
Nature Reviews Endocrinology
5(11):
633–638.
Di Marzo V and
Fontana A
(1995)
Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’.
Prostaglandins Leukot Essent Fatty Acids
53(1):
1–11.
Di Marzo V,
Fontana A,
Cadas H et al.
(1994)
Formation and inactivation of endogenous cannabinoid anandamide in central neurons.
Nature
372(6507):
686–669.
Di Marzo V,
Ligresti A and
Cristino L
(2009)
The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation.
International Journal of Obesity
33(suppl. 2):
S18–24.
Dinh TP,
Freund TF and
Piomelli D
(2002)
A role for monoglyceride lipase in 2‐arachidonoylglycerol inactivation.
Chemistry and Physics of Lipids
121(1–2):
149–158.
Gao Y,
Vasilyev DV,
Goncalves MB et al.
(2010)
Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock‐out mice.
Journal of Neuroscience
30(6):
2017–2024.
Grimaldi P,
Orlando P,
Di Siena S et al.
(2009)
The endocannabinoid system and pivotal role of the CB2 receptor in mouse spermatogenesis.
Proceedings of the National Academy of Sciences of the United States of America
106(27):
11131–11136.
Guindon J and
Hohmann AG
(2009)
The endocannabinoid system and pain.
CNS & Neurological Disorders Drug Targets
8(6):
403–421.
Hill MN,
Patel S,
Campolongo P et al.
(2010)
Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output.
Journal of Neuroscience
30(45):
14980–14986.
Idris AI and
Ralston SH
(2009)
Cannabinoids and bone: friend or foe?
Calcified Tissue International
87(4):
285–297.
Izzo AA and
Camilleri M
(2009)
Cannabinoids in intestinal inflammation and cancer.
Pharmacological Research
60(2):
117–125.
Jiang S,
Alberich‐Jorda M,
Zagozdzon R et al.
(2011)
Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization.
Blood
117(3):
827–838.
Karasu T,
Marczylo TH,
Maccarrone M,
Konje JC,
(2011)
The role of sex steroid hormones, cytokines and the endocannabinoid system in female fertility.
Human Reproduction Update
17(3):
347–361.
Karsak M,
Cohen‐Solal M,
Freudenberg J et al.
(2005)
Cannabinoid receptor type 2 gene is associated with human osteoporosis.
Human Molecular Genetics
14(22):
3389–3396.
Ligresti A,
De Petrocellis L,
Hernán Pérez de la Ossa D et al.
(2010)
Exploiting nanotechnologies and TRPV1 channels to investigate the putative anandamide membrane transporter.
PLoS One
5(4):
e10239.
Maccarrone M,
Barboni B,
Paradisi A et al.
(2005)
Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction.
Journal of Cell Science
118(part 19):
4393–4404.
Mackie K
(2008)
Cannabinoid receptors: where they are and what they do.
Journal of Neuroendocrinology
20(suppl. 1):
10–14.
Maione S,
Bisogno T,
de Novellis V et al.
(2006)
Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type‐1 receptors.
Journal of Pharmacology and Experimental Therapeutics
316(3):
969–982.
Malfitano AM,
Ciaglia E and
Gangemi G
(2011)
Update on the endocannabinoid system as an anticancer target.
Expert Opinion on Therapeutic Targets [Epub ahead of print].
Marrs WR,
Blankman JL,
Horne EA et al.
(2010)
The serine hydrolase ABHD6 controls the accumulation and efficacy of 2‐AG at cannabinoid receptors.
Nature Neuroscience
13(8):
951–957.
Matias I,
Chen J,
De Petrocellis L and
Bisogno T
(2004)
Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism.
Journal of Pharmacology and Experimental Therapeutics
309(2):
745–757.
Matsuda LA,
Lolait SJ,
Brownstein MJ et al.
(1990)
Structure of a cannabinoid receptor and functional expression of the cloned cDNA.
Nature
346(6284):
561–564.
Mechoulam R,
Ben‐Shabat S,
Hanus L et al.
(1995)
Identification of an endogenous 2‐monoglyceride, present in canine gut, that binds to cannabinoid receptors.
Biochemical Pharmacology
50(1):
83–90.
Mechoulam R,
Devane WA,
Breuer A et al.
(1991)
A random walk through a cannabis field.
Pharmacology Biochemistry and Behavior
40(3):
461–464.
Min R,
Di Marzo V and
Mansvelder HD
(2010)
DAG lipase involvement in depolarization‐induced suppression of inhibition: does endocannabinoid biosynthesis always meet the demand?
Neuroscientist
16(6):
608–613.
Moreira FA and
Crippa JA
(2009)
The psychiatric side‐effects of rimonabant.
Revista Brasileira de Psiquiatria
31(2):
145–153.
Muccioli GG,
Naslain D,
Bäckhed F et al.
(2010)
The endocannabinoid system links gut microbiota to adipogenesis.
Molecular Systems Biology
6:
392.
Munro S,
Thomas KL and
Abu‐Shaar M
(1993)
Molecular characterization of a peripheral receptor for cannabinoids.
Nature
365(6441):
61–65.
Okamoto Y,
Tsuboi K and
Ueda N
(2009)
Enzymatic formation of anandamide.
Vitamins and Hormones
81:
1–24.
Pacher P and
Steffens S
(2010)
The emerging role of the endocannabinoid system in cardiovascular disease.
Seminars in Immunopathology
31(1):
63–77.
Pandey R,
Mousawy K,
Nagarkatti M et al.
(2009)
Endocannabinoids and immune regulation.
Pharmacological Research
60(2):
85–92.
Parolaro D,
Realini N,
Vigano D et al.
(2010)
The endocannabinoid system and psychiatric disorders.
Experimental Neurology
224(1):
3–14.
Pertwee RG
(2009)
Emerging strategies for exploiting cannabinoid receptor agonists as medicines.
British Journal of Pharmacology
156(3):
397–411.
Petrosino S and
Di Marzo V
(2010)
FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels.
Current Opinion in Investigational Drugs
11(1):
51–62.
Rossi F,
Bellini G,
Luongo L et al.
(2011)
The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy.
Bone
48(5):
997–1007.
Sagar DR,
Gaw AG,
Okine BN et al.
(2009)
Dynamic regulation of the endocannabinoid system: implications for analgesia.
Molecular Pain
5:
59.
Schlosburg JE,
Blankman JL,
Long JZ et al.
(2010)
Chronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system.
Nature Neuroscience
13(9):
1113–1119.
Simon GM and
Cravatt BF
(2010)
Characterization of mice lacking candidate N‐acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo.
Molecular BioSystems
6(8):
1411–1418.
Sugiura T and
Waku K
(1995)
2‐Arachidonoylglycerol and the cannabinoid receptors.
Chemistry and Physics of Lipids
108(1‐2):
89–106.
Sun X and
Dey SK
(2009)
Cannabinoid/endocannabinoid signaling impact on early pregnancy events.
Current Topics in Behavioral Neurosciences
1:
255–273.
Tam J,
Vemuri VK,
Liu J et al.
(2010)
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity.
Journal of Clinical Investigation
120(8):
2953–2966.
Tanimura A,
Yamazaki M,
Hashimotodani Y et al.
(2010)
The endocannabinoid 2‐arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission.
Neuron
65(3):
320–327.
Vellani V,
Petrosino S,
De Petrocellis L et al.
(2008)
Functional lipidomics. Calcium‐independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin.
Neuropharmacology
55(8):
1274–1279.
Vila A,
Rosengarth A,
Piomelli D et al.
(2007)
Hydrolysis of prostaglandin glycerol esters by the endocannabinoid‐hydrolyzing enzymes, monoacylglycerol lipase and fatty acid amide hydrolase.
Biochemistry
46(33):
9578–9585.
Wettschureck N,
van der Stelt M,
Tsubokawa H et al.
(2006)
Forebrain‐specific inactivation of Gq/G11 family G proteins results in age‐dependent epilepsy and impaired endocannabinoid formation.
Molecular and Cellular Biology
26(15):
5888–5894.
Yates ML and
Barker EL
(2009)
Organized trafficking of anandamide and related lipids.
Vitamins and Hormones
81:
25–53.
Zhang L,
Wang M,
Bisogno T et al.
(2011)
Endocannabinoids generated by Ca2+ or by metabotropic glutamate receptors appear to arise from different pools of diacylglycerol lipase.
Plos One
6(1):
e1635.